Advertisement
Steroidsupply

Zytiga/Abiratas/Abiraterone acetate CAS 154229-18-2 Treat pr

May 24th, 2017
578
0
Never
Not a member of Pastebin yet? Sign Up, it unlocks many cool features!
text 5.47 KB | None | 0 0
  1. Zytiga/Abiratas/Abiraterone acetate CAS 154229-18-2 Treat prostate cancer;
  2.  
  3. Email:kathelin@yccreate.com
  4. Skype:live:kathelin_4
  5. WhatsApp:+86-188 7222 0706
  6.  
  7.  
  8. product Name: Abiraterone Acetate
  9. Synonyms: (3)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol Acetate (Ester); Abiraterone Acetate; CB 7630; (3beta,8xi,9xi,14xi)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate; Zytiga, Abiratas, Abretone, Abirapro
  10. MF: C26H33NO2
  11. MW: 391.5457
  12. CAS: 154229-18-2
  13.  
  14. Abiraterone Acetate Description:
  15. Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (previously called hormone-resistant or hormone-refractory prostate cancer) - i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists. It is a prodrug to the active agent abiraterone, and is marketed by Janssen Biotech under the trade name Zytiga. In addition, Intas Pharmaceuticals markets the drug under the trade name Abiratas, Cadila Pharmaceuticals markets the drug as Abretone, and Glenmark Pharmaceuticals as Abirapro.
  16.  
  17. Medical uses:
  18. Abiraterone acetate is indicated for use in combination with prednisone as a treatment for metastatic castration-resistant prostate cancer. In Australia it is covered by the Pharmaceutical Benefits Scheme when being used to treat castration-resistant prostate cancer and given in combination with (subject to the conditions that the patient is not currently receiving chemotherapy, is either resistant or intolerant of docetaxel, has a WHO performance status of <2, and his disease has not since become progressive since treatment with PBS-subsidised abiraterone acetate has commenced).
  19.  
  20. Mechanism of action:
  21. Abiraterone, the active metabolite of abiraterone acetate, inhibits CYP17A1, which manifests as two enzymes, 17-hydroxylase (IC50 = 2.5 nM) and 17,20-lyase (IC50 = 15 nM) (six-fold more selective for inhibition of 17-hydroxylase over 17,20-lyase) that are expressed in testicular, adrenal, and prostatic tumor tissues. CYP17 catalyzes two sequential reactions: (a) the conversion of pregnenolone and progesterone to their 17-hydroxy derivatives by its 17-hydroxylase activity, and (b) the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by its 17,20-lyase activity. DHEA and androstenedione are androgens and precursors of testosterone. Inhibition of CYP17 activity by abiraterone thus decreases circulating levels of androgens
  22.  
  23. Abiraterone also acts as a partial antagonist of androgen receptors, and as an inhibitor of the enzymes 3β-hydroxysteroid dehydrogenase, CYP11B1 (steroid 11β-hydroxylase), and other CYP450s (e.g., CYP1A2, CYP2C9, and CYP3A4).
  24.  
  25. Application:
  26.  
  27. Abiraterone acetate is indicated for use in combination with prednisone as a treatment for metastatic castration-resistant prostate cancer. It has received FDA (28 April 2011), EMA (23 September 2011), MHRA (5 September 2011) and TGA (1 March 2012) approval for this indication In Australia it is covered by the Pharmaceutical Benefits Scheme when being used to treat castration-resistant prostate cancer and given in combination withprednisone/prednisolone (subject to the conditions that the patient is not currently receiving chemotherapy, is either resistant or intolerant of docetaxel, has a WHO performance status of <2, and his disease has not since become progressive since treatment with PBS-subsidised abiraterone acetate has commenced).
  28.  
  29.  
  30.  
  31. Our advantages:
  32. Over 15years specialized in this field,Professional & Experienced sevices provided.
  33. 1. Best prices with High quality.We have complete QA&QC system;steroid powder purity is more than 99% hplc. We use the right recipe to cook the injectable steroid oil. All our order will send out after passing the test exam.
  34. 2. Rich experienced in delivering the parcels to you.The most disguise package and the most professional shipping company to ensure safe delivery. .
  35. 3. Enough stock ensure the prompt delivery time.
  36. 4. Good after-sales service.
  37. 5. Specials are possible when the order is big enough.
  38. 6. The most important thing is that we have resend policy to protect you 100%.
  39.  
  40. Packaging & Delivery:
  41. We have professional team for package and shipment. Special way to ship 100 grams to 100kg powders at one time to your country. Fast and discreet shipment could be arranged for customs pass Guaranteed.
  42. Payment & Shipping Terms:
  43. Minimum Order Quantity:25KG (25KG/Drum
  44. Price:Negotiable
  45. Packing:25kg/drum or as required
  46. Delivery Time: within 24hours after receiving full payment.
  47. Payment terms:T/T,Western Union,MoneyGram.
  48. Supply ability:200kg/month
  49.  
  50. How to proceed an order:
  51. 1st: Please let me know what you need-Which product/Cas No. quantity, and the destination country.
  52. 2nd: You send us the purchase order once we cme to an agreement on all details.
  53. 3rd: Parcel would be delivered upon full payment received.
  54. 4th: Express Tracking No.will be provided about the parcels.
  55. 5th: You will get the parcels in 7days.
  56. 6th: After-sales service would be provided after you receive parcels.
  57.  
  58. Should you have any inquires please feel free to contact me ,kathelin(at) yccreate(doc)com.
  59.  
  60. anti-cancer raw powders:
  61. Axitinib CAS No 319460-85-0
  62. Lapatinib CAS 231277-92-2
  63. Erlotinib Hydrochloride CAS: 183319-69-9
  64. Gefitini CAS No.: 184475-35-2
  65. Sunitinib Malate CAS 341031-54-7
  66. Cabozantinib 849217-68-1
  67. Bibw2992 Dimaleate CAS:850140-73-7
Advertisement
Add Comment
Please, Sign In to add comment
Advertisement